Disposition of 9956 shares by Xiaodong Wang of BeiGene at 185.73 subject to Rule 16b-3
BGNE Stock | USD 181.89 2.79 1.51% |
About 55% of BeiGene's investor base is interested to short. The analysis of the overall investor sentiment regarding BeiGene suggests that many traders are impartial. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
Filed transaction by BeiGene Director, Other: Chair, Scientific Advisory Brd. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at businesswire.com
BeiGene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeiGene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
BeiGene is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
AKRO | Akero Therapeutics | 1.16 | ||||
BMRN | Biomarin Pharmaceutical | 0.19 | ||||
INCY | Incyte | 0.47 | ||||
KRYS | Krystal Biotech | 0.75 | ||||
APLS | Apellis Pharmaceuticals | 0.85 | ||||
LEGN | Legend Biotech | 0.88 | ||||
IONS | Ionis Pharmaceuticals | 1.16 | ||||
ASND | Ascendis Pharma | 2.00 | ||||
IMAB | I Mab | 2.22 | ||||
BPMC | Blueprint Medicines | 2.42 | ||||
TVTX | Travere Therapeutics | 2.81 | ||||
ARWR | Arrowhead Pharmaceuticals | 2.92 | ||||
IMVT | Immunovant | 4.82 | ||||
PCVX | Vaxcyte | 5.61 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |